18 Apr 2019 --- Swiss multinational Lonza is continuing its positive momentum in its newly aligned segment, Lonza Pharma Biotech & Nutrition (LPBN), according to a first-quarter overview. However, the company’s recently created Specialty Ingredients (LSI) portfolio faced challenges with the business performing below expectations. Despite facing some continued headwinds in LSI, Lonza maintains its outlook for 2019 based on the strong performance of its core healthcare businesses.